Informations générales (source: ClinicalTrials.gov)
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Interventional
Phase 3
Bristol-Myers Squibb (Voir sur ClinicalTrials)
février 2025
septembre 2031
02 octobre 2025
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489
(Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus
Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy
in Participants with Extensive-Stage Small Cell Lung Cancer.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Christos CHOUAID | 28/08/2025 15:20:03 | Contacter | ||
Critères
Tous
Inclusion Criteria
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer
(ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no
help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging
techniques like a CT scan or MRI at a site other than the brain and nervous system
Exclusion Criteria
- Participants have already received certain types of treatment for extensive stage
small cell lung cancer
- Participants have certain health conditions, like spread of small cell lung cancer
to the brain that are causing symptoms, certain lung diseases, heart diseases,
infections, autoimmune diseases, other cancers, or a type of nerve damage called
peripheral sensory neuropathy
- Other protocol-defined Inclusion/Exclusion criteria apply.
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer
(ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no
help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging
techniques like a CT scan or MRI at a site other than the brain and nervous system
Exclusion Criteria
- Participants have already received certain types of treatment for extensive stage
small cell lung cancer
- Participants have certain health conditions, like spread of small cell lung cancer
to the brain that are causing symptoms, certain lung diseases, heart diseases,
infections, autoimmune diseases, other cancers, or a type of nerve damage called
peripheral sensory neuropathy
- Other protocol-defined Inclusion/Exclusion criteria apply.